CytomX Therapeutics Inc (CTMX)

Name: CytomX Therapeutics Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2026-03-31

Latest Quarter

2026-03-31

Revenue

$10.3M

Net Income

-$18.2M

Operating Margin

-191.8%

Free Cash Flow

-$75.8M

Debt / Assets

34.7%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for CytomX Therapeutics Inc (CTMX).
Income Statement (Quarterly)	2026-03-31	2025-03-31	2024-12-31	2024-09-30
Revenue	10,258,000	50,917,000	38,093,000	33,432,000
Cost of Revenue	251,000	0	0	0
Gross Profit	10,007,000	50,917,000	38,093,000	33,432,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	10,692,000	9,428,000	5,624,000	7,953,000
Operating Expenses	29,679,000	28,296,000	20,414,000	29,321,000
Operating Income	-19,672,000	22,621,000	17,679,000	4,111,000
Interest Expense	0	0	0	0
Income Before Tax	-18,189,000	23,587,000	18,938,000	5,797,000
Income Tax Expense	59,000	62,000	62,000	61,000
Net Income	-18,248,000	23,525,000	18,876,000	5,736,000
Per Share
EPS	-0.10	0.27	0.22	0.07
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for CytomX Therapeutics Inc (CTMX).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	76,201,000	138,103,000	101,214,000	53,163,000	69,573,000
Cost of Revenue	0	0	0	5,856,000	0
Gross Profit	76,201,000	138,103,000	101,214,000	47,307,000	69,573,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	29,837,000	29,726,000	30,018,000	42,849,000	39,160,000
Operating Expenses	98,565,000	113,108,000	107,698,000	154,498,000	153,354,000
Operating Income	-22,364,000	24,995,000	-6,484,000	-101,335,000	-83,781,000
Interest Expense	0	0	0	-2,018,000	0
Income Before Tax	-17,130,000	32,093,000	3,323,000	-99,317,000	-83,609,000
Income Tax Expense	238,000	224,000	3,892,000	-2,018,000	0
Net Income	-17,368,000	31,869,000	-569,000	-97,299,000	-83,609,000
Per Share
EPS	-0.15	0.38	-0.01	-1.48	-1.30
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for CytomX Therapeutics Inc (CTMX).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	12,667,000	38,052,000	17,171,000	193,650,000
Short Term Investments	124,385,000	62,571,000	157,338,000	0
Net Receivables	2,013,000	3,103,000	3,432,000	35,986,000
Inventory	0	0	0	0
Total Current Assets	143,921,000	107,305,000	182,936,000	237,102,000
Property Plant Equipment	4,700,000	10,603,000	16,178,000	21,021,000
Goodwill and Intangibles	1,387,000	1,532,000	1,678,000	1,824,000
Total Assets	151,566,000	120,533,000	205,151,000	260,891,000
Liabilities
Account Payables	1,301,000	1,088,000	1,458,000	2,809,000
Short Term Debt	4,240,000	10,290,000	4,589,000	4,082,000
Total Current Liabilities	46,615,000	85,772,000	155,913,000	152,608,000
Long Term Debt	0	4,240,000	9,385,000	13,975,000
Total Liabilities	52,558,000	120,989,000	252,598,000	346,642,000
Shareholders Equity
Retained Earnings	-711,949,000	-691,579,000	-723,448,000	-722,879,000
Total Shareholders Equity	99,008,000	-456,000	-47,447,000	-85,751,000

Balance sheet annual history for CytomX Therapeutics Inc (CTMX).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	12,667,000	38,052,000	17,171,000	193,650,000	205,530,000
Short Term Investments	124,385,000	62,571,000	157,338,000	0	99,696,000
Net Receivables	2,013,000	3,103,000	3,432,000	35,986,000	790,000
Inventory	0	0	0	0	0
Total Current Assets	143,921,000	107,305,000	182,936,000	237,102,000	310,301,000
Property Plant Equipment	4,700,000	10,603,000	16,178,000	21,021,000	25,322,000
Goodwill and Intangibles	1,387,000	1,532,000	1,678,000	1,824,000	1,970,000
Total Assets	151,566,000	120,533,000	205,151,000	260,891,000	339,411,000
Liabilities
Account Payables	1,301,000	1,088,000	1,458,000	2,809,000	2,818,000
Short Term Debt	4,240,000	10,290,000	4,589,000	4,082,000	3,618,000
Total Current Liabilities	46,615,000	85,772,000	155,913,000	152,608,000	106,316,000
Long Term Debt	0	4,240,000	9,385,000	13,975,000	18,056,000
Total Liabilities	52,558,000	120,989,000	252,598,000	346,642,000	250,032,000
Shareholders Equity
Retained Earnings	-711,949,000	-691,579,000	-723,448,000	-722,879,000	-533,724,000
Total Shareholders Equity	99,008,000	-456,000	-47,447,000	-85,751,000	89,379,000

Cash flow quarterly history for CytomX Therapeutics Inc (CTMX).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-20,370,000	31,869,000	-569,000	-99,317,000
Depreciation & Amortization	146,000	1,768,000	2,175,000	2,443,000
Stock Based Compensation	6,302,000	7,668,000	8,558,000	13,125,000
Change in Working Capital	-68,576,000	-126,415,000	-62,509,000	-30,654,000
Operating Cash Flow	-75,587,000	-86,231,000	-56,035,000	-110,788,000
Investing Activities
Capital Expenditure	-220,000	-310,000	-840,000	-1,740,000
Investments	-220,000	-310,000	-840,000	-1,740,000
Investing Cash Flow	-59,744,000	99,700,000	-150,674,000	98,260,000
Financing Activities
Debt Repayment	0	0	0	0
Common Stock Issued/Repurchased	110,446,000	6,909,000	30,230,000	648,000
Dividends Paid	-3,002,000	0	0	0
Financing Cash Flow	110,446,000	7,522,000	30,230,000	648,000
Summary
Free Cash Flow	-75,807,000	-86,541,000	-56,875,000	-112,528,000
Net Change in Cash	-24,885,000	20,991,000	-176,479,000	-11,880,000

Cash flow annual history for CytomX Therapeutics Inc (CTMX).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	-20,370,000	31,869,000	-569,000	-99,317,000	-83,609,000
Depreciation & Amortization	146,000	1,768,000	2,175,000	2,443,000	2,706,000
Stock Based Compensation	6,302,000	7,668,000	8,558,000	13,125,000	13,167,000
Change in Working Capital	-68,576,000	-126,415,000	-62,509,000	-30,654,000	-54,700,000
Operating Cash Flow	-75,587,000	-86,231,000	-56,035,000	-110,788,000	-119,031,000
Investing Activities
Capital Expenditure	-220,000	-310,000	-840,000	-1,740,000	-1,609,000
Investments	-220,000	-310,000	-840,000	-1,740,000	-1,609,000
Investing Cash Flow	-59,744,000	99,700,000	-150,674,000	98,260,000	22,489,000
Financing Activities
Debt Repayment	0	0	0	0	0
Common Stock Issued/Repurchased	110,446,000	6,909,000	30,230,000	648,000	107,712,000
Dividends Paid	-3,002,000	0	0	0	0
Financing Cash Flow	110,446,000	7,522,000	30,230,000	648,000	110,213,000
Summary
Free Cash Flow	-75,807,000	-86,541,000	-56,875,000	-112,528,000	-120,640,000
Net Change in Cash	-24,885,000	20,991,000	-176,479,000	-11,880,000	13,671,000